Ryan Schoenfeld, Chief Executive Officer of The Mark Foundation for Cancer Research, shared on LinkedIn:
“Last week in D.C., I joined fellow funders and researchers at the Milken Institute’s 2026 Future of Health Summit for a SPARC Collective session on advancing biomedical discovery through bold investment.
Our conversation zeroed in on a persistent bottleneck in cancer research: traditional funding often waits until an idea feels safe, leaving a massive gap between promising early discovery and the clinic. Filling that gap is where strategic philanthropy can make the biggest difference.
I shared a couple of examples of how we lean into that space at The Mark Foundation for Cancer Research:
- Backing early, unproven science-like our foundational investments in in vivo CAR-T-before the broader market is ready to step in.
- Building coalitions that align multiple funders around hard problems (like early detection of cancer) that no single organization can tackle effectively alone.

As The Mark Foundation approaches its 10th anniversary, we’re thinking a lot about where we need to take even bigger risks to move the needle for cancer patients
Thank you to Milken Institute Strategic Philanthropy and the Science Philanthropy Accelerator for Research and Collaboration (SPARC) teams for bringing together such a great group of leaders and to my fellow panelists for a thought-provoking conversation.”
Other articles from Ryan Schoenfeld on OncoDaily.